Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial

OBJECTIVE: We aimed to investigate whether anakinra, an interleukin-1receptor inhibitor, could improve outcome in moderate COVID-19 patients. METHODS: In this controlled, open-label trial, we enrolled adults with COVID-19 requiring oxygen. We randomly assigned patients to receive intravenous anakinr...

Descripción completa

Detalles Bibliográficos
Autores principales: Audemard-Verger, Alexandra, Le Gouge, Amélie, Pestre, Vincent, Courjon, Johan, Langlois, Vincent, Vareil, Marc-Olivier, Devaux, Mathilde, Bienvenu, Boris, Leroy, Vincent, Goulabchand, Radjiv, Colombain, Léa, Bigot, Adrien, Guimard, Thomas, Douadi, Youcef, Urbanski, Geoffrey, Faucher, Jean François, Maulin, Laurence, Lioger, Bertrand, Talarmin, Jean-Philippe, Groh, Matthieu, Emmerich, Joseph, Deriaz, Sophie, Ferreira-Maldent, Nicole, Cook, Ann-Rose, Lengellé, Céline, Bourgoin, Hélène, Mekinian, Arsène, Aouba, Achille, Maillot, François, Caille, Agnès
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351999/
https://www.ncbi.nlm.nih.gov/pubmed/35925914
http://dx.doi.org/10.1371/journal.pone.0269065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351999/
https://www.ncbi.nlm.nih.gov/pubmed/35925914
http://dx.doi.org/10.1371/journal.pone.0269065

Ejemplares similares